ArticleJournal of cardiothoracic surgery2026
LDCT combined with serum miR-4638-3p expression enhances NSCLC diagnostic efficacy and rs6601178 polymorphism susceptibility association.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite reducing lung cancer mortality, low-dose computed tomography (LDCT) is limited by a high false positive rate. This study integrates serum miR-4638-3p with LDCT to assess its diagnostic value in non-small cell lung cancer (NSCLC), explore miR-4638-3p's mechanisms, and analyze the rs6601178 polymorphism's association with NSCLC susceptibility.
methodsParticipants comprised 152 healthy controls (HC), 152 patients with benign lung disease (BLD), and 152 NSCLC patients. Serum miR-4638-3p and PTEN levels were measured by RT-qPCR; LDCT scans were performed and interpreted according to established clinical protocols; rs6601178 genotyping was performed using PCR-RFLP. Statistical analyses included logistic regression, ROC analysis, and AUC comparisons. Cell function was detected using CCK-8 and Transwell methods, and the mechanism was explored using PPI analysis and dual-luciferase reporter experiments.
resultsmiR-4638-3p expression was significantly elevated in NSCLC compared to BLD and HC groups and emerged as a robust independent predictor for distinguishing BLD from NSCLC. LDCT alone demonstrated moderate diagnostic performance, while miR-4638-3p alone exhibited higher accuracy. Combining both modalities significantly enhanced diagnostic efficacy. The rs6601178 A allele frequency was reduced in NSCLC relative to HC. The AA genotype was associated with decreased risks of poor tumor differentiation, lymph node metastasis, and advanced-stage disease (III/IV). Knockdown of miR-4638-3p inhibited the proliferation, migration and invasion of NSCLC and validated PTEN as its direct target gene.
conclusionSerum miR-4638-3p serves as a potent diagnostic biomarker for NSCLC. Its integration with LDCT significantly improves diagnostic accuracy, potentially decreasing unnecessary invasive interventions. The rs6601178 A allele confers protection against both NSCLC development and progression. Mechanistically, knockdown of miR-4638-3p inhibits tumour cell biological functions and may act by targeting PTEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.